| Literature DB >> 25584891 |
Ton N Schumacher1, Can Kesmir2, Marit M van Buuren3.
Abstract
Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25584891 DOI： 10.1016/j.ccell.2014.12.004
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743